MX2022009493A - Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. - Google Patents
Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas.Info
- Publication number
- MX2022009493A MX2022009493A MX2022009493A MX2022009493A MX2022009493A MX 2022009493 A MX2022009493 A MX 2022009493A MX 2022009493 A MX2022009493 A MX 2022009493A MX 2022009493 A MX2022009493 A MX 2022009493A MX 2022009493 A MX2022009493 A MX 2022009493A
- Authority
- MX
- Mexico
- Prior art keywords
- affinity
- binding domain
- tcr
- same
- antibody binding
- Prior art date
Links
- 102000025850 HLA-A2 Antigen Human genes 0.000 abstract 4
- 108010074032 HLA-A2 Antigen Proteins 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3053—Skin, nerves, brain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/5743—Specifically defined cancers of skin, e.g. melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
Abstract
Se proporcionan entidades de unión de afinidad que tienen un dominio de unión a TCRL y procedimientos para su uso. Más específicamente, estas composiciones se unen a células HLA-A2/WT1+, HLA-A2/MAGE-A4, HLA-A2/MAGE-A9, HLA-A2/PAP o HLA-A2/TyrD+ y, como tal, pueden usarse en diagnóstico y terapia.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562172264P | 2015-06-08 | 2015-06-08 | |
NL2014935A NL2014935B1 (en) | 2015-06-08 | 2015-06-08 | T cell receptor like antibodies having fine specificity. |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022009493A true MX2022009493A (es) | 2022-12-13 |
Family
ID=54325627
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015928A MX2017015928A (es) | 2015-06-08 | 2016-06-08 | Anticuerpos similares al receptor de celulas t que tienen una especificidad fina. |
MX2017015801A MX2017015801A (es) | 2015-06-08 | 2016-06-08 | Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. |
MX2022009493A MX2022009493A (es) | 2015-06-08 | 2017-12-06 | Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017015928A MX2017015928A (es) | 2015-06-08 | 2016-06-08 | Anticuerpos similares al receptor de celulas t que tienen una especificidad fina. |
MX2017015801A MX2017015801A (es) | 2015-06-08 | 2016-06-08 | Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. |
Country Status (13)
Country | Link |
---|---|
US (2) | US11001642B2 (es) |
EP (3) | EP3302538B1 (es) |
JP (5) | JP7013243B2 (es) |
KR (2) | KR20180012851A (es) |
CN (4) | CN114437217A (es) |
AU (3) | AU2016276556C1 (es) |
CA (3) | CA2988270A1 (es) |
ES (1) | ES2922236T3 (es) |
IL (3) | IL256178B2 (es) |
MX (3) | MX2017015928A (es) |
NL (1) | NL2014935B1 (es) |
SG (1) | SG10202007398PA (es) |
WO (2) | WO2016199140A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA48487B1 (fr) | 2014-12-23 | 2021-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie contre le carcinome hépatocellulaire (hcc) et d'autres cancers |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
AU2016342041B2 (en) | 2015-10-23 | 2021-12-02 | Eureka Therapeutics, Inc. | Antibody/T-cell receptor chimeric constructs and uses thereof |
CN110809580A (zh) * | 2017-01-24 | 2020-02-18 | 安贝科思生物制剂公司 | 用于靶向癌症中包含非典型hla-i和新抗原的复合体的方法和组合物 |
CN110741016A (zh) | 2017-04-26 | 2020-01-31 | 优瑞科生物技术公司 | 嵌合抗体/t-细胞受体构筑体及其用途 |
CA3063905A1 (en) * | 2017-05-16 | 2018-11-22 | The Johns Hopkins University | Manabodies and methods of using |
KR102412805B1 (ko) * | 2017-05-31 | 2022-06-27 | 크라제 메디컬 씨오 리미티드 | 세포 면역 요법을 위한 조성물 및 방법 |
BR112019025667A2 (pt) * | 2017-06-05 | 2020-09-01 | Mie University | proteína de ligação ao antígeno que reconhece o peptídeo derivado de mage-a4 |
CA3066972A1 (en) * | 2017-06-14 | 2018-12-20 | Adicet Bio Inc. | Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof |
CN109776671B (zh) * | 2017-11-14 | 2022-05-27 | 杭州康万达医药科技有限公司 | 分离的t细胞受体、其修饰的细胞、编码核酸、表达载体、制备方法、药物组合物和应用 |
TWI805665B (zh) * | 2017-12-21 | 2023-06-21 | 瑞士商赫孚孟拉羅股份公司 | 結合hla-a2/wt1之抗體 |
WO2019165307A1 (en) * | 2018-02-23 | 2019-08-29 | Abexxa Biologics, Inc. | Combination cancer therapy with anti-cancer agents and antibodies targeting a complex comprising non-classical hla-i and neoantigen |
GB201803750D0 (en) | 2018-03-08 | 2018-04-25 | Immunocore Ltd | Method |
US20210238543A1 (en) * | 2018-06-04 | 2021-08-05 | Apo-T B.V. | Methods and means for attracting immune effector cells to tumor cells |
US11939381B2 (en) * | 2018-07-19 | 2024-03-26 | Eli Lilly And Company | Bispecific antibodies targeting immune checkpoints |
JP7156653B2 (ja) * | 2018-08-30 | 2022-10-19 | イノベイティブ セルラー セラピューティクス ホールディングス,エルティディ | 固形腫瘍を治療するためのキメラ抗原受容体細胞 |
CN113272016A (zh) * | 2018-10-01 | 2021-08-17 | 阿迪塞特生物股份有限公司 | 关于治疗实体肿瘤的工程化和非工程化γδ-T细胞的组合物和方法 |
EP3860645A1 (en) | 2018-10-01 | 2021-08-11 | Adicet Bio Inc. | Compositions and methods regarding engineered and non- engineered gamma-delta t cells for treatment of hematological tumors |
WO2020194195A1 (en) * | 2019-03-25 | 2020-10-01 | University Health Network | T cell receptors and methods of use thereof |
CN114585646A (zh) * | 2019-06-18 | 2022-06-03 | 里珍纳龙药品有限公司 | Mage-a4 t细胞受体及其使用方法 |
MX2022000896A (es) * | 2019-07-24 | 2022-02-14 | Regeneron Pharma | Receptores de antigenos quimericos con especificidad por mage-a4 y usos de los mismos. |
US20210048442A1 (en) | 2019-08-13 | 2021-02-18 | Immatics Biotechnologies Gmbh | Method for the characterization of peptide:mhc binding polypeptides |
CN112442119B (zh) * | 2019-09-05 | 2023-02-24 | 香雪生命科学技术(广东)有限公司 | 一种识别ssx2的高亲和力t细胞受体 |
CN110563804A (zh) * | 2019-09-19 | 2019-12-13 | 河南省农业科学院 | 基于天然免疫库筛选识别氧氟沙星单链抗体的多肽序列及应用 |
NL2024375B1 (en) * | 2019-12-04 | 2021-08-31 | Apo T B V | Methods and means for attracting immune effector cells to tumor cells. |
JP7296467B2 (ja) | 2019-12-18 | 2023-06-22 | エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト | Hla-a2/mage-a4に結合する抗体 |
IL297874A (en) | 2020-05-05 | 2023-01-01 | Regeneron Pharma | Car containing cd28 zeta and cd3 zeta |
IL276599A (en) | 2020-08-09 | 2022-03-01 | Yeda Res & Dev | T cell receptor unique to mage-a1 and its uses |
US20220340894A1 (en) * | 2021-03-09 | 2022-10-27 | Cdr-Life Ag | Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same |
CA3210289A1 (en) | 2021-03-09 | 2022-09-15 | Anna Maria SOBIERAJ | Mage-a4 peptide-mhc antigen binding proteins |
AU2022271212A1 (en) * | 2021-05-04 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
TW202339797A (zh) * | 2021-12-14 | 2023-10-16 | 瑞士商赫孚孟拉羅股份公司 | 使用hla-a2mage-a4xcd3雙特異性抗體及4-1bb(cd137)促效劑治療癌症 |
US20240091262A1 (en) | 2022-09-14 | 2024-03-21 | Cdr-Life Ag | Mage-a4 peptide dual t cell engagers |
Family Cites Families (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
US8258260B2 (en) | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
US3940475A (en) | 1970-06-11 | 1976-02-24 | Biological Developments, Inc. | Radioimmune method of assaying quantitatively for a hapten |
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4289747A (en) | 1978-12-26 | 1981-09-15 | E-Y Laboratories, Inc. | Immunological determination using lectin |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
ES2108048T3 (es) | 1990-08-29 | 1997-12-16 | Genpharm Int | Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos. |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
US20020150914A1 (en) | 1995-06-30 | 2002-10-17 | Kobenhavns Universitet | Recombinant antibodies from a phage display library, directed against a peptide-MHC complex |
EP0857176A1 (en) | 1995-10-25 | 1998-08-12 | Centocor B.V. | HUMAN EPITHELIAL ANTIGEN Ep-CAM DERIVED PEPTIDES AND THEIR USE |
WO2000020445A2 (en) | 1998-10-02 | 2000-04-13 | Ludwig Institute For Cancer Research | Tumor antigens and ctl clones isolated by a novel procedure |
US7157091B1 (en) * | 1999-06-18 | 2007-01-02 | Ludwig Institute For Cancer Research | MAGE-A1 peptides presented by HLA class II molecules |
US7521202B2 (en) | 1999-12-17 | 2009-04-21 | The Board Of Regents Of The University Of Oklahoma | Method and apparatus for the production of soluble MHC antigens and uses thereof |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
US20070099182A1 (en) | 2000-10-10 | 2007-05-03 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
US20090062512A1 (en) | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
US20070026433A1 (en) | 2001-03-09 | 2007-02-01 | Hildebrand William H | Epitope testing using soluble HLA |
US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
US6992176B2 (en) | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
JP2005533486A (ja) | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Mhc−ペプチド複合体結合リガンド |
DE10225144A1 (de) | 2002-05-29 | 2003-12-18 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
DE10313819A1 (de) | 2003-03-24 | 2004-10-07 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
US7488793B2 (en) | 2003-09-22 | 2009-02-10 | Ludwig Institute For Cancer Research | Isolated peptide which binds to HLA-Cw*07 and uses thereof |
NZ550810A (en) | 2004-05-19 | 2009-05-31 | Immunocore Ltd | High affinity NY-ESO T cell receptor |
DE102004026135A1 (de) | 2004-05-25 | 2006-01-05 | Immatics Biotechnologies Gmbh | An MHC-Moleküle bindende Tumor-assoziierte Peptide |
ATE430164T1 (de) | 2004-05-26 | 2009-05-15 | Immunocore Ltd | Hochaffine telomerase-t-zellen-rezeptoren |
GB0411773D0 (en) | 2004-05-26 | 2004-06-30 | Avidex Ltd | Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex |
US20090226474A1 (en) | 2004-05-27 | 2009-09-10 | Weidanz Jon A | Antibodies as T cell receptor mimics, methods of production and uses thereof |
EP1642905B1 (en) | 2004-10-02 | 2009-01-21 | Immatics Biotechnologies GmbH | Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes |
TW200636064A (en) | 2004-10-28 | 2006-10-16 | Centocor Inc | Anti-respiratory syncytial virus antibodies, antigens and uses thereof |
AU2006228308B2 (en) | 2005-04-01 | 2012-05-17 | Adaptimmune Limited | High affinity HIV T cell receptors |
ATE512160T1 (de) | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
GB0524477D0 (en) | 2005-11-30 | 2006-01-11 | Avidex Ltd | Isolated T cell receptors which specifically bind to vygfvracl-hla-24 |
GB0511124D0 (en) | 2005-06-01 | 2005-07-06 | Avidex Ltd | High affinity melan-a t cell receptors |
PT1806359E (pt) | 2005-09-05 | 2010-05-25 | Immatics Biotechnologies Gmbh | Peptídeos associados a tumor ligando promiscuamente às moléculas do antigénio de leucócitos humanos (hla) da classe ii |
EP2305827A1 (en) * | 2005-11-14 | 2011-04-06 | Université Laval | Cancer antigen MAGE-A9 and uses thereof |
WO2007143104A2 (en) | 2006-06-01 | 2007-12-13 | Receptor Logic, Ltd. | Antibodies as t cell receptor mimics, methods of production and uses thereof |
DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
WO2008120202A2 (en) | 2007-03-29 | 2008-10-09 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
PT2183361E (pt) | 2007-07-27 | 2015-09-11 | Immatics Biotechnologies Gmbh | Nova imunoterapia para tumores neuronais e cerebrais |
US7994276B2 (en) | 2007-07-27 | 2011-08-09 | Immatics Biotechnologies Gmbh | Composition of tumour-associated peptides and related anti-cancer vaccine |
NZ582822A (en) | 2007-07-27 | 2012-06-29 | Immatics Biotechnologies Gmbh | Novel immunogenic epitopes for immunotherapy |
WO2009026117A2 (en) | 2007-08-16 | 2009-02-26 | Glaxo Group Limited | Novel compounds |
WO2009090651A2 (en) | 2008-01-15 | 2009-07-23 | Technion Research And Development Foundation Ltd. | Major histocompatibility complex hla-b2705 ligands useful for therapy and diagnosis |
DE602008000891D1 (de) | 2008-04-30 | 2010-05-12 | Immatics Biotechnologies Gmbh | Neuartige Formulierungen von Tumor-assoziierten Peptiden, welche an menschliche Leukozytenantigene der Klasse I oder II für Impfungen binden |
HUE024541T2 (hu) | 2008-05-14 | 2016-01-28 | Immatics Biotechnologies Gmbh | Szurvivinbõl és neurocanból származó új és hatásos II-es osztályú MHC peptidek |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
JP2012521761A (ja) | 2009-03-25 | 2012-09-20 | アルター・バイオサイエンス・コーポレーション | Hivvpr−特異的t細胞受容体 |
GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
EP2501722A4 (en) | 2009-11-19 | 2013-05-01 | Univ Singapore | METHOD FOR PRODUCING MONOCLONAL ANTIBODIES LIKE T-LYMPHOCYTE RECEPTORS AND USES THEREOF |
US9023802B2 (en) | 2009-12-14 | 2015-05-05 | Immatics Biotechnologies Gmbh | HLA-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
GB201019331D0 (en) | 2010-03-19 | 2010-12-29 | Immatics Biotechnologies Gmbh | Methods for the diagnosis and treatment of cancer based on AVL9 |
JP2013531476A (ja) * | 2010-04-30 | 2013-08-08 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | ヒトにおける免疫原性が低下した抗体 |
US9821073B2 (en) * | 2010-12-27 | 2017-11-21 | Apo-T B.V. | Polypeptide that binds aberrant cells and induces apoptosis |
EA201401134A1 (ru) | 2011-02-11 | 2015-05-29 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Hla-рестиктированные пептидоспецифические антигенсвязывающие белки |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
WO2015070061A1 (en) | 2013-11-07 | 2015-05-14 | Memorial Sloan-Kettering Cancer Center | Anti-wt1/hla bi-specific antibody |
WO2012135854A2 (en) | 2011-04-01 | 2012-10-04 | Memorial Sloan-Kettering Cancer Center | Antibodies to cytosolic peptides |
SG10201705698PA (en) * | 2012-01-13 | 2017-08-30 | Apo-T B V | Aberrant Cell-Restricted Immunoglobulins Provided With A Toxic Moiety |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
GB201223172D0 (en) | 2012-12-21 | 2013-02-06 | Immunocore Ltd | Method |
AU2014346648A1 (en) | 2013-11-07 | 2016-06-23 | Eureka Therapeutics, Inc. | Fc-enhanced anti-WT1/HLA antibody |
SG10201913158PA (en) | 2015-04-03 | 2020-02-27 | Eureka Therapeutics Inc | Constructs targeting afp peptide/mhc complexes and uses thereof |
US20180179283A1 (en) | 2015-06-08 | 2018-06-28 | Adicet Bio Inc. | T cell receptor like antibodies having fine specificity |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
CA3066972A1 (en) | 2017-06-14 | 2018-12-20 | Adicet Bio Inc. | Antibodies capable of binding hla-a2/tyrd in an hla restricted manner and uses thereof |
-
2015
- 2015-06-08 NL NL2014935A patent/NL2014935B1/en active
-
2016
- 2016-06-08 CN CN202210030010.4A patent/CN114437217A/zh active Pending
- 2016-06-08 EP EP16739266.1A patent/EP3302538B1/en active Active
- 2016-06-08 CN CN201680040163.XA patent/CN108025045B/zh active Active
- 2016-06-08 CA CA2988270A patent/CA2988270A1/en active Pending
- 2016-06-08 AU AU2016276556A patent/AU2016276556C1/en active Active
- 2016-06-08 MX MX2017015928A patent/MX2017015928A/es unknown
- 2016-06-08 CN CN202210349590.3A patent/CN114605547A/zh active Pending
- 2016-06-08 KR KR1020187000504A patent/KR20180012851A/ko not_active Application Discontinuation
- 2016-06-08 AU AU2016276555A patent/AU2016276555B2/en active Active
- 2016-06-08 WO PCT/IL2016/050599 patent/WO2016199140A1/en active Application Filing
- 2016-06-08 JP JP2017563328A patent/JP7013243B2/ja active Active
- 2016-06-08 MX MX2017015801A patent/MX2017015801A/es unknown
- 2016-06-08 EP EP22154188.1A patent/EP4039270A1/en active Pending
- 2016-06-08 WO PCT/IL2016/050600 patent/WO2016199141A2/en active Application Filing
- 2016-06-08 CA CA2987889A patent/CA2987889A1/en active Pending
- 2016-06-08 KR KR1020177037826A patent/KR20180011275A/ko not_active Application Discontinuation
- 2016-06-08 JP JP2017563331A patent/JP6912392B2/ja active Active
- 2016-06-08 IL IL256178A patent/IL256178B2/en unknown
- 2016-06-08 ES ES16739266T patent/ES2922236T3/es active Active
- 2016-06-08 CA CA3220475A patent/CA3220475A1/en active Pending
- 2016-06-08 EP EP16734763.2A patent/EP3302537A1/en active Pending
- 2016-06-08 SG SG10202007398PA patent/SG10202007398PA/en unknown
- 2016-06-08 US US15/579,616 patent/US11001642B2/en active Active
- 2016-06-08 CN CN201680039192.4A patent/CN107847569A/zh active Pending
-
2017
- 2017-12-06 MX MX2022009493A patent/MX2022009493A/es unknown
- 2017-12-07 IL IL256177A patent/IL256177A/en unknown
-
2021
- 2021-05-11 US US17/317,824 patent/US20210388111A1/en active Pending
- 2021-07-08 JP JP2021113633A patent/JP7147018B2/ja active Active
-
2022
- 2022-09-21 JP JP2022150286A patent/JP7376655B2/ja active Active
- 2022-11-11 AU AU2022268398A patent/AU2022268398A1/en active Pending
-
2023
- 2023-07-30 IL IL304821A patent/IL304821A/en unknown
- 2023-10-26 JP JP2023183842A patent/JP2024016092A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022009493A (es) | Entidades de afinidad que comprenden un dominio de union de anticuerpo similar al tcr con alta afinidad y especificidad fina y usos de las mismas. | |
PH12018502113A1 (en) | Chimeric receptors and methods of use thereof | |
PH12018502118A1 (en) | Chimeric receptors to flt3 and methods of use thereof | |
PH12016501644B1 (en) | Binding proteins and methods of use thereof | |
MX2018008369A (es) | Anticuerpos de anti-miostatina pro/latente y metodo de uso de los mismos. | |
MX2016017271A (es) | Moleculas con especificidad para cd45 y cd79. | |
MA40408A (fr) | Molécules ayant une spécificité pour cd79 et cd22 | |
EA201691824A1 (ru) | АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ | |
EP3954710A3 (en) | Antibodies to canine interleukin-4 receptor alpha | |
EA201390011A1 (ru) | Т-клеточные рецепторы | |
MA40527A (fr) | Protéines de liaison à l'antigène se liant à wisp5 | |
MX2015012872A (es) | Anticuerpos anti-tau y metodos de uso. | |
WO2018119425A3 (en) | Anti-lilrb3 antibodies and methods of use thereof | |
MX2020010951A (es) | Anticuerpos anti-hla-g y utilizacion de los mismos. | |
MX2018010771A (es) | Moleculas de union al transcrito 7 similar a inmunoglobulina (ilt7) y metodos de uso de las mismas. | |
PH12021550120A1 (en) | Chimeric receptors to steap1 and methods of use thereof | |
NZ702285A (en) | Staphylococcal coagulase antigens and methods of their use | |
PH12019550194A1 (en) | Anti-ceacam1 antibody and use thereof | |
MX2021000287A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000280A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2021000288A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. | |
MX2016014726A (es) | Proteinas de union al antigeno her1 que se unen a la beta-horquilla de her1. | |
MX2019007356A (es) | Polipeptidos de union y metodos para fabricarlos. | |
MX2021000305A (es) | Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente. |